acyclovir
acycl
analogu
nucleosid
guanosin
convert
activ
form
initi
monophosphoryl
virusencod
thymidin
kinas
tk
although
normal
human
cell
possess
tk
affin
acyclovir
viral
tk
approxim
time
greater
human
tk
monophosph
undergo
two
addit
host
cell
enzymemedi
phosphoryl
acyclovir
triphosph
acycloguanosin
triphosph
preferenti
inhibit
viral
dna
polymeras
competit
chain
termin
higher
concentr
activ
form
infect
cell
affin
viral
polymeras
result
low
toxic
normal
host
cell
valacyclovir
lvalyl
ester
prodrug
acyclovir
addit
lvalyl
ester
foster
greater
oral
absorpt
valacyclovir
convert
acyclovir
prodrug
provid
three
five
time
greater
bioavail
oral
acyclovir
acyclovir
valacyclovir
use
princip
treat
infect
caus
herp
simplex
viru
hsv
chapter
varicellazost
viru
vzv
chapter
depend
countri
acyclovir
avail
topic
ointment
cream
oral
capsul
intraven
ophthalm
formul
valacyclovir
avail
oral
capsul
oral
acyclovir
valacyclovir
decreas
durat
symptom
approxim
reduc
durat
viral
shed
initi
episod
genit
herp
two
day
therapi
appear
suffici
recurr
genit
herp
chronic
suppress
highli
effect
reduc
clinic
viral
recurr
valacyclovir
reduc
risk
transmiss
genit
hsv
heterosexu
partner
herp
labiali
cold
sore
day
therapi
oral
valacyclovir
improv
time
heal
reduc
pain
wherea
acyclovir
ointment
consist
clinic
benefit
parenter
acyclovir
indic
initi
treatment
mucos
cutan
hsv
infect
immunocompromis
patient
neonat
hsv
infect
dissemin
organinvas
infect
immunocompet
patient
subsequ
switch
oral
valacyclovir
possibl
circumst
highdos
parenter
acyclovir
therapi
choic
treatment
hsv
enceph
acyclovir
also
effect
treatment
vzv
infect
although
higher
dose
need
mucos
hsv
infect
see
tabl
adult
treat
within
hour
develop
varicella
rash
acyclovir
decreas
sever
diseas
number
lesion
oral
valacyclovir
may
effect
oral
acyclovir
intraven
acyclovir
warrant
initi
treatment
varicella
zoster
immunocompromis
host
acyclovir
chemoprophylaxi
valacyclovir
chemoprophylaxi
reduc
incid
recurr
hsv
recipi
stem
cell
solid
organ
transplant
valacyclovir
superior
prevent
cytomegaloviru
cmv
diseas
acyclovir
valacyclovir
excel
safeti
profil
gener
well
toler
common
side
effect
includ
nausea
vomit
headach
major
advers
effect
includ
renal
dysfunct
central
nervou
system
cn
toxic
dehydr
preexist
renal
dysfunct
predispos
develop
renal
impair
neurolog
side
effect
includ
tremor
myoclonu
confus
lethargi
agit
hallucin
renal
dysfunct
predispos
develop
neurotox
neutropenia
sign
bone
marrow
toxic
also
report
rare
despit
widespread
use
acyclovir
develop
hsv
resist
immunocompet
subject
uncommon
preval
howev
antivir
resist
higher
immunocompromis
subject
includ
hiv
infect
preval
bone
marrow
transplant
preval
drugresist
refractori
vzv
infect
occur
highli
immunocompromis
patient
intraven
foscarnet
cidofovir
may
effect
infect
caus
acyclovirresist
virus
penciclovir
acycl
guanin
analogu
unlik
acyclovir
oblig
chain
termin
may
incorpor
dna
penciclovir
phosphoryl
viral
tk
penciclovir
monophosph
convert
penciclovir
triphosph
penciclovir
demonstr
vitro
activ
vzv
hsv
compar
acyclovir
bioavail
penciclovir
oral
administr
less
contrast
famciclovir
oral
prodrug
deacetyl
oxid
liver
form
penciclovir
bioavail
penciclovir
averag
administr
famciclovir
penciclovir
famciclovir
use
treat
hsv
vzv
infect
penciclovir
avail
topic
cream
countri
intraven
formul
famciclovir
avail
capsul
frequent
applic
topic
penciclovir
reduc
herp
labiali
pain
lesion
day
famciclovir
approv
treatment
recurr
hsv
labiali
genit
infect
herp
zoster
effect
valacyclovir
also
effect
acyclovir
use
treat
initi
genit
hsv
infect
penciclovir
well
toler
topic
cream
major
advers
reaction
local
irrit
mild
erythema
advers
effect
oral
famciclovir
includ
headach
dizzi
nausea
diarrhea
first
episod
acyclovir
po
mg
tid
mg
timesday
day
famciclovir
po
mg
tid
day
valacyclovir
po
g
bid
day
recurr
acyclovir
po
mg
tid
day
mg
tid
mg
timesday
day
famciclovir
po
mg
bid
dose
valacyclovir
po
mg
bid
penciclovir
resist
hsv
uncommon
immunocompet
subject
like
acyclovir
resist
frequent
immunocompromis
host
acyclovirresist
hsv
isol
crossresist
penciclovir
ganciclovir
acycl
deoxyguanosin
analogu
antivir
activ
multipl
herpesvirus
includ
hsv
vzv
cmv
chapter
epsteinbarr
viru
ebv
chapter
human
herpesviru
much
activ
acyclovir
cmv
ebv
bioavail
oral
ganciclovir
less
oral
administr
valganciclovir
lvalyl
prodrug
ganciclovir
bioavail
ganciclovir
averag
ganciclovir
avail
oral
capsul
parenter
inject
ocular
implant
valganciclovir
avail
tablet
ganciclovir
valganciclovir
effect
treatment
cmv
retin
compar
activ
absenc
immun
reconstitut
longterm
suppress
therapi
necessari
also
use
lifethreaten
cmv
diseas
patient
acquir
immunodefici
syndrom
aid
immunocompromis
condit
prevent
cmv
diseas
transplant
patient
immunocompromis
patient
organinvas
cmv
infect
intraven
ganciclovir
provid
clinic
respons
rate
although
respons
rate
lower
cmv
pneumon
stem
cell
transplant
cmv
enceph
patient
aid
oral
valganciclovir
provid
longterm
outcom
similar
intraven
ganciclovir
treatment
cmv
diseas
longterm
prophylaxi
ganciclovir
valganciclovir
reduc
incid
cmv
diseas
solid
organ
stem
cell
transplant
therapi
substanti
side
effect
includ
bone
marrow
suppress
drug
also
use
preemptiv
therapi
patient
cmv
viremia
antigenemia
prevent
cmv
diseas
preemptiv
valganciclovir
therapi
may
equal
effect
chronic
valacyclovir
prophylaxi
intraven
ganciclovir
recommend
agent
treatment
herpesviru
b
infect
particularli
involv
cn
common
advers
effect
ganciclovir
valganciclovir
bone
marrow
suppress
particularli
neutropenia
thrombocytopenia
occur
patient
given
intraven
ganciclovir
fever
edema
phlebiti
headach
neuropathi
disorient
nausea
anorexia
rash
myalgia
also
report
ganciclovir
therapi
intravitr
ganciclovir
implant
may
caus
vitreou
hemorrhag
retin
detach
ganciclovir
resist
secondari
mutat
cmv
kinas
sometim
dna
polymeras
relat
length
ganciclovir
exposur
degre
immunosuppress
resist
may
associ
progress
diseas
continu
ganciclovir
use
foscarnet
cidofovir
altern
treatment
cidofovir
acycl
phosphon
deriv
cytosin
phosphoryl
activ
diphosph
form
host
cellular
enzym
cidofovir
diphosph
competit
inhibit
viral
dna
polymeras
viral
dna
synthesi
despit
short
serum
halflif
antivir
effect
protract
prolong
intracellular
concentr
phosphoryl
metabolit
cidofovir
commerci
avail
intraven
infus
investig
use
includ
topic
gel
intravitr
intralesion
inject
intraven
cidofovir
indic
aid
patient
cmv
retin
ganciclovir
foscarnet
therapi
fail
limit
data
suggest
intraven
cidofovir
may
effect
cmv
infect
pneumon
gastroenter
acycloviror
foscarnetresist
hsv
infect
certain
form
human
papillomaviru
diseas
invas
adenovir
infect
transplant
recipi
possibl
bk
viru
infect
renal
transplant
patient
addit
vivo
anim
data
suggest
efficaci
cidofovir
smallpox
vaccinia
monkeypox
infect
although
clinic
trial
lack
doserel
nephrotox
character
increas
serum
creatinin
proteinuria
tubular
dysfunct
main
side
effect
intraven
cidofovir
adequ
hydrat
concomit
oral
probenecid
reduc
risk
common
side
effect
includ
diarrhea
asthenia
nausea
vomit
neutropenia
fever
rash
iriti
intraocular
pressur
chang
loss
visual
acuiti
uveiti
report
intraven
cidofovir
intravitr
cidofovir
effect
local
toxic
sustain
exposur
cidofovir
easili
induc
resist
although
resist
infrequ
describ
hsv
cmv
foscarnet
pyrophosph
analogu
act
noncompetit
inhibitor
mani
viral
rna
dna
polymeras
nucleotid
incorpor
dna
rna
strand
polymeras
pyrophosph
releas
foscarnet
directli
inhibit
viral
polymeras
without
phosphoryl
tkdefici
acyclovirresist
hsv
vzv
suscept
agent
foscarnet
effect
ganciclovir
treatment
cmv
retin
patient
aid
combin
therapi
ganciclovir
may
superior
monotherapi
either
agent
recalcitr
retin
extraretin
cmv
diseas
foscarnet
demonstr
efficaci
similar
ganciclovir
choic
agent
may
dictat
side
effect
profil
foscarnet
also
effect
treatment
acyclovirresist
hsv
vzv
infect
nephrotox
azotemia
proteinuria
dose
limit
occur
third
patient
slow
infus
rate
salin
hydrat
reduc
risk
common
side
effect
includ
anemia
patient
granulocytopenia
diarrhea
nausea
vomit
fever
seizur
paresthesia
headach
genit
ulcer
mark
electrolyt
disturb
may
develop
includ
hypophosphatemia
hypocalcemia
hypokalemia
hypomagnesemia
foscarnet
prolong
qt
interv
associ
cardiac
arrhythmia
includ
ventricular
tachycardia
ventricular
fibril
torsad
de
point
develop
cmv
resist
foscarnet
result
mutat
viral
dna
polymeras
uncommon
except
prolong
administr
aid
patient
retin
foscarnet
resist
detect
patient
month
month
fomivirsen
antisens
oligonucleotid
inhibit
cmv
replic
current
avail
intravitr
inject
effect
newli
diagnos
cmv
retin
cmv
retin
fail
usual
therapi
although
direct
comparison
agent
lack
intravitr
administr
fomivirsen
may
caus
increas
intraocular
pressur
iriti
vitreiti
cataract
patient
brivudin
also
known
bromovinyldeoxyuridin
thymidin
analogu
current
licens
treatment
herp
zoster
sever
european
union
countri
unit
state
efficaci
compar
acyclovir
similar
time
crust
cessat
pain
common
side
effect
includ
nausea
vomit
abdomin
discomfort
anorexia
docosanol
satur
fatti
alcohol
inhibit
intracellular
penetr
lipid
envelop
virus
approv
cream
treatment
herp
labiali
frequent
topic
applic
shown
reduct
time
cessat
pain
heal
direct
comparison
agent
lack
local
reaction
rash
pruritu
common
side
effect
idoxuridin
trifluorothymidin
trifluridin
thymidin
analogu
phosphoryl
viral
cellular
tk
activ
triphosph
deriv
inhibit
viral
cellular
dna
synthesi
result
antivir
activ
also
host
cytotox
prevent
safe
system
use
howev
toler
compound
adequ
topic
use
idoxuridin
trifluorothymidin
avail
ophthalm
formul
licens
treatment
herpet
kerat
direct
comparison
trifluridin
appear
efficaci
compound
addit
idoxuridin
dimethyl
sulfoxid
use
topic
countri
treatment
mucos
herp
infect
frequent
advers
effect
trifluridin
transient
burn
sting
instil
palpebr
edema
irrit
punctat
corneal
defect
report
idoxuridin
vidarabin
adenosin
analogu
avail
ophthalm
ointment
indic
acut
keratoconjunct
recurr
epitheli
kerat
secondari
hsv
clinic
activ
appear
superior
idoxuridin
toxic
ointment
includ
conjunctiv
inject
burn
irrit
amantadin
rimantadin
symmetr
tricycl
amin
activ
mani
influenza
virus
chapter
inhibit
ion
channel
function
protein
influenza
interfer
uncoat
viru
releas
viral
genom
amantadin
rimantadin
tabl
decreas
length
sever
uncompl
influenza
viru
infect
suscept
strain
initi
within
first
day
onset
symptom
uncertain
whether
reduc
risk
complic
drug
formul
oral
administr
capsul
amantadin
tablet
rimantadin
well
pediatr
syrup
recent
year
mark
increas
antivir
resist
commun
isol
limit
util
drug
rimantadin
amantadin
effect
use
prophylaxi
influenza
ill
overal
averag
rimantadin
amantadin
person
take
drug
prophylaxi
subclin
infect
may
still
develop
elicit
immun
respons
protect
expos
antigen
relat
virus
amantadin
also
use
treatment
parkinson
druginduc
extrapyramid
reaction
manag
multipl
sclerosi
symptom
amantadin
caus
cn
side
effect
healthi
young
adult
take
standard
adult
dose
mgday
frequenc
significantli
lower
rimantadin
neuropsychiatr
side
effect
includ
anxieti
nervous
insomnia
particularli
elderli
renal
insuffici
hallucin
confus
disorient
psychosi
coma
amantadin
less
often
rimantadin
associ
increas
risk
seizur
drug
caus
gastrointestin
side
effect
orthostat
hypotens
occur
anticholinerg
side
effect
includ
dri
mouth
occur
amantadin
recipi
zanamivir
oseltamivir
peramivir
sialic
acid
analogu
inhibit
influenza
viru
neuraminidas
competit
interact
activ
enzym
site
influenza
b
virus
includ
adamantineresist
strain
influenza
neuraminidas
cleav
termin
sialic
acid
residu
destroy
receptor
recogn
viral
hemagglutinin
drug
inhibit
action
essenti
releas
viru
infect
cell
prevent
viral
aggreg
spread
within
respiratori
tract
oseltamivir
administ
oral
phosphat
prodrug
rapidli
absorb
hydrolyz
activ
form
oseltamivir
carboxyl
oral
bioavail
zanamivir
poor
current
licens
deliv
oral
inhal
powder
peramivir
intraven
neuraminidas
inhibitor
licens
previous
made
avail
use
emerg
use
author
mechan
us
food
drug
administr
fda
allow
use
unapprov
medic
product
certain
type
emerg
pandem
influenza
oseltamivir
zanamivir
effect
treatment
prophylaxi
acut
influenza
b
infect
earli
treatment
adult
decreas
durat
sever
ill
reduc
lower
respiratori
tract
complic
antibiot
use
oseltamivir
hospit
cohort
studi
treatment
oseltamivir
associ
signific
reduct
death
odd
ratio
zanamivir
also
effect
allevi
symptom
decreas
risk
lower
respiratori
complic
zanamivir
oseltamivir
highli
effect
prevent
influenza
peramivir
may
use
patient
respond
either
oseltamivir
zanamivir
antivir
therapi
common
side
effect
oseltamivir
nausea
vomit
may
also
associ
headach
rash
possibl
abnorm
transaminas
zanamivir
gener
well
toler
bronchospasm
sometim
sever
report
primarili
patient
underli
airway
diseas
common
side
effect
peramivir
nausea
diarrhea
mild
neutropenia
oseltamivir
resist
result
neuraminidas
mutat
detect
treatment
season
influenza
often
children
adult
recent
patient
immunocompromis
host
possibl
individu
develop
resist
associ
treatment
failur
zanamivir
retain
clinic
effect
common
oseltamivirresist
variant
adefovir
acycl
analogu
adenosin
monophosph
administ
oral
prodrug
adefovir
dipivoxil
rapidli
convert
enzymat
adefovir
intestin
epithelium
chronic
hepat
b
chapter
prolong
administr
adefovir
effect
improv
histolog
abnorm
liver
decreas
hepat
b
viru
hbv
dna
level
normal
biochem
alanin
aminotransferas
marker
patient
hepat
b
e
antigen
hbeag
posit
hbeagneg
chronic
hepat
b
tabl
adefovir
shown
effect
chronic
hepat
b
resist
lamivudin
combin
lamivudin
adefovir
may
decreas
emerg
resist
viru
addit
synergist
antivir
activ
major
advers
effect
nephrotox
manifest
increas
serum
creatinin
sometim
hypophosphatemia
usual
revers
discontinu
drug
common
side
effect
includ
asthenia
headach
nausea
vomit
diarrhea
addit
sever
exacerb
hepat
b
observ
cessat
therapi
adefovir
resist
secondari
point
mutat
hbv
polymeras
develop
patient
year
adefovir
therapi
lamivudin
gener
retain
activ
adefovirresist
variant
entecavir
deoxyguanosin
nucleosid
analogu
specif
antivir
activ
hepadnavirus
potent
lamivudin
also
retain
activ
lamivudineresist
hbv
variant
well
absorb
oral
administr
prolong
halflif
hour
allow
oncedaili
dose
entecavir
approv
treatment
chronic
hepat
b
adult
evid
activ
viral
replic
either
persist
elev
serum
aminotransferas
histolog
activ
diseas
compar
lamivudin
entecavir
efficaci
reduc
hbv
dna
level
normal
serum
aminotransferas
well
improv
histolog
abnorm
higher
dose
longer
durat
therapi
indic
lamivudineresist
infect
entecavir
recommend
patient
hivhbv
coinfect
receiv
concurr
highli
activ
antiretrovir
therapi
risk
resist
hiv
nucleosid
revers
transcriptas
inhibitor
advers
effect
report
entecavir
therapi
includ
headach
fatigu
dizzi
nausea
abdomin
pain
rhiniti
fever
diarrhea
cough
myalgia
lactic
acidosi
sever
hepatomegali
steatosi
report
sever
exacerb
hepat
b
observ
cessat
therapi
entecavir
resist
caus
specif
mutat
hbv
polymeras
appear
uncommon
evid
year
drug
exposur
lamivudin
deoxycytidin
nucleosid
analogu
activ
retrovirus
hepadnavirus
triphosph
inhibit
hbv
polymeras
incorpor
viral
dna
result
termin
dna
chain
prolong
lamivudin
administr
patient
chronic
hepat
b
suppress
viral
replic
improv
histolog
abnorm
liver
reduc
progress
fibrosi
decreas
risk
late
complic
monotherapi
lamivudin
appear
inferior
monotherapi
interferon
sustain
control
hbv
replic
combin
therapi
lamivudin
interferon
shown
inconsist
benefit
compar
either
drug
alon
advers
effect
lamivudin
includ
diarrhea
headach
elev
liver
enzym
sever
posttreat
exacerb
hepat
b
includ
fatal
occur
discontinu
lamivudin
commonli
patient
coinfect
hbv
hiv
lamivudin
resist
caus
mutat
hbv
polymeras
common
prolong
treatment
hepat
b
emerg
treat
patient
annual
resist
associ
increas
viral
replic
aminotransferas
tenofovir
nucleotid
analogu
adenosin
monophosph
commerci
avail
agent
tenofovir
disoproxil
fumar
ester
prodrug
tenofovir
give
effect
tenofovir
bioavail
treatment
tenofovir
effect
adefovir
produc
histolog
improv
viral
suppress
patient
hbeagneg
hbeagposit
chronic
hepat
b
hbvhiv
coinfect
combin
antiretrovir
therapi
includ
tenofovir
lead
significantli
reduc
hbv
dna
level
compar
combin
therapi
adefovir
tenofovir
gener
well
toler
common
side
effect
nausea
diarrhea
vomit
anorexia
lactic
acidosi
hepat
steatosi
report
primarili
use
combin
nucleosid
analogu
acut
exacerb
hepat
b
report
discontinu
tenofovir
patient
coinfect
hiv
hbv
mutat
hbv
polymeras
confer
reduc
suscept
tenofovir
occur
prolong
use
month
although
clinic
signific
mutat
remain
defin
telbivudin
synthet
thymidin
nucleosid
analogu
activ
hbv
includ
lamivudineresist
variant
triphosph
form
competit
inhibit
hbv
dna
polymeras
revers
transcriptas
telbivudin
use
treatment
chronic
hepat
b
compar
trial
lamivudin
adefovir
telbivudin
demonstr
greater
virolog
respons
week
vs
subject
hbv
dna
neg
polymeras
chain
reaction
analysi
common
side
effect
includ
headach
nausea
vomit
sever
acut
exacerb
hepat
b
report
patient
discontinu
antihbv
therapi
myopathi
manifest
muscl
ach
weak
increas
creatin
kinas
rare
report
ribavirin
purin
nucleosid
antivir
activ
dna
virus
mani
rna
virus
includ
influenza
b
parainfluenza
measl
respiratori
syncyti
viru
rsv
retrovirus
arenavirus
lassa
viru
hantavirus
monotherapi
ribavirin
chronic
hepat
c
chapter
shown
decreas
serum
alanin
aminotransferas
hepat
c
viru
rna
level
howev
combin
therapi
ribavirin
variou
interferon
recent
pegyl
interferon
superior
interferon
monotherapi
improv
viral
clearanc
liver
histolog
respons
reduc
complic
includ
mortal
ribavirin
plu
pegyl
interferon
becom
standard
treatment
chronic
hepat
c
aerosol
administr
ribavirin
use
treat
rsv
bronchiol
pneumonia
children
treat
influenza
b
infect
limit
benefit
seen
oral
ribavirin
uncompl
influenza
aerosol
ribavirin
combin
intraven
immun
globulin
particularli
antirsv
monoclon
antibodi
palivizumab
appear
reduc
mortal
rsv
infect
bone
marrow
transplant
highli
immunocompromis
patient
system
ribavirin
reduc
mortal
associ
lassa
fever
asian
korean
hemorrhag
fever
renal
syndrom
chapter
although
mortal
patient
hantavirusassoci
cardiopulmonari
syndrom
appear
activ
congocrimean
hemorrhag
fever
nipah
viru
infect
ribavirin
often
recommend
treatment
hemorrhag
fever
unknown
etiolog
secondari
arenavirus
bunyavirus
event
virus
use
biolog
weapon
aerosol
deliveri
may
caus
bronchospasm
system
ribavirin
frequent
associ
hemolyt
anemia
seri
sometim
electrolyt
abnorm
includ
hypocalcemia
hypomagnesemia
arrhythmia
pruritu
rash
nausea
myalgia
report
neurolog
side
effect
includ
insomnia
irrit
ribavirin
gonadotox
teratogen
multipl
speci
emtricitabin
analogu
cytidin
current
licens
treatment
hiv
infect
howev
larg
studi
patient
chronic
hepat
b
monotherapi
emtricitabin
led
significantli
better
histolog
respons
vs
virolog
suppress
vs
week
compar
placebo
interferon
glycoprotein
cytokin
complex
array
antivir
immunomodul
antineoplast
properti
interferon
current
classifi
natur
sourc
class
gener
leukocyt
fibroblast
lymphocyt
respect
type
interferon
produc
recombin
dna
technolog
although
full
mechan
interferon
action
defin
interferon
gener
induc
synthesi
new
cellular
rna
protein
mediat
antivir
effect
multipl
differ
mechan
interferon
gener
requir
administr
daili
sever
time
per
week
howev
combin
interferon
polyethylen
glycol
form
pegyl
interferon
significantli
prolong
absorpt
decreas
elimin
provid
higher
sustain
plasma
level
enabl
administr
weekli
chronic
activ
hepat
b
treatment
interferon
alfa
lead
loss
hbv
dna
biochem
histolog
improv
patient
administr
peginterferon
week
convert
patient
seroneg
statu
month
treatment
combin
therapi
interferon
lamivudin
clearli
superior
interferon
alon
contrast
hepat
b
combin
therapi
mainstay
treatment
hepat
c
subcutan
administr
peginterferon
plu
daili
ribavirin
week
result
sustain
virolog
respons
treat
patient
compar
less
respons
interferon
monotherapi
patient
hepat
c
genotyp
lower
level
respons
patient
genotyp
vs
patient
genotyp
may
need
week
combin
therapi
shorter
durat
therapi
week
lower
sustain
virolog
respons
common
side
effect
interferon
administr
includ
influenzalik
symptom
fever
chill
headach
malais
symptom
usual
becom
less
sever
repeat
treatment
toler
develop
patient
within
sever
week
major
toxic
includ
bone
marrow
suppress
primarili
granulocytopenia
thrombocytopenia
gener
revers
therapi
discontinu
neuropsychiatr
disturb
may
manifest
depress
anxieti
somnol
confus
behavior
disturb
side
effect
includ
profound
fatigu
anorexia
weight
loss
hypothyroid
hyperthyroid
alopecia
cardiotox
arrhythmia
revers
cardiomyopathi
imiquimod
relat
compound
resiquimod
topic
immun
respons
modifi
lack
direct
antivir
effect
instead
agent
induc
activ
immun
cell
monocyt
macrophag
natur
killer
cell
produc
antivir
cytokin
particularli
tumor
necrosi
topic
imiquimod
cream
approv
treatment
anogenit
wart
chapter
immunocompet
patient
imiquimod
lead
complet
clearanc
wart
patient
may
also
benefici
patient
refractori
cutan
leishmaniasi
chapter
molluscum
contagiosum
chapter
administ
topic
cream
three
time
weekli
maximum
week
wash
hour
applic
side
effect
primarili
local
includ
erythema
irrit
tender
less
often
eros
side
effect
usual
resolv
cessat
drug
